2 Beaten-Down Biotech Stocks That Could Make You Filthy Rich
Biotech stocks are going through a historic drawdown at the moment. Nearly 400 publicly traded biotech companies have lost 40% or more of their value in just the past six months. The market's irrational behavior toward all things biotech, however, isn't necessarily a bad thing for patient investors. Many of these beaten-down biotech stocks will ultimately rebound.
Which unloved biotech stocks are the most compelling buys amid this industrywide downturn? While there are scores of intriguing bargains in biotech right now, Gritstone bio (NASDAQ: GRTS) and Sorrento Therapeutics (NASDAQ: SRNE) both have the potential to deliver life-changing gains for risk-tolerant investors. Here is a brief overview on the key value drivers associated with each stock.
Image source: Getty Images.
Source Fool.com
